Life Sciences

Lessons from the supply chain

10/2021
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds. But, behind the headlines, how is the pandemic affecting attitudes to risk?
supply chain

From governments to corporates, the importance of a diversified supply chain has been a big lesson of the pandemic. At the start, the global supply chain was tested as governments around the world urgently tried to buy personal protective equipment (PPE), test kits and other medical devices. With various countries limiting exports of products from drugs to PPE, the tension between national priorities and globalised free markets has become abundantly clear.

For governments, ways to manage health security more closely and bring production of life science products closer to home will be a big question as the dust settles on this pandemic. For life science companies, a focus on local supply and diversification are two key themes in corporate risk mitigation efforts, after experiencing first-hand the risks posed to their supply chains by government interventions, lockdowns and competition for resources.

With attention shifting to vaccines, the downstream supply chain is now where some of the most significant risks reside. With some vaccines needing to be stored at very cold temperatures, the pressure is on within the supply chain. If temperatures, among other parameters such as vibration and humidity, are not properly maintained when drugs are transported, it can lead to batches being thrown away.

Read the “Lessons from the Supply Chain” report to get an insight into how sourcing challenges during the pandemic is changing attitudes to risk in the supply chain, and ultimately changing the shape of the supply chain itself.

Key takeaways

  • Tensions over vaccine supply timelines emphasize the importance of drafting clear contracts.
  • Claims arise when pharma products fall outside of set parameters, such as temperature limits, during transit.
  • If a shipment’s value includes research and development (R&D) costs, liability can become contentious.
  • From governments to corporates, diversification of suppliers and near-shoring are being discussed.
Report

Lessons from the supply chain

Insights and expertise

We keep you informed — and your business protected — with these helpful articles.
holding lame and lamelle in front of a microscope
Life science in the era of pandemics : 2 years on
Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.
medical devices
Making medical devices during a pandemic
How has the coronavirus pandemic affected the risk profile of medical device manufacturing?
telehealth
The great telehealth experiment
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
solution bottles
3 life science supply chain lessons from the COVID-19 pandemic
3 life science lessons to help identify vulnerabilities in end-to-end supply chain companies.

Have a question or need more information?

Leave your contact details and our representatives will get in touch with you.